RxDoctor Payments Data

Sarah Talbott

Physician Assistant · Holland, MINPI 1447816863

Payments from drug & device makers

$1,266in general payments, 2019–2025

Across 49 payments — averaging $25.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$316
  • AbbVie$227
  • Janssen Scientific Affairs, LLC$117
  • Boston Scientific$113
  • Ardelyx, Inc.$109
  • Madrigal Pharmaceuticals$104
  • plus $279 from 6 others

What the payments were for

  • Food & beverage$1,266100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,266 in reported general payments places this provider in the 75th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$13,878
Medicare patients
100
Services billed
154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase17$59,032
LinzessLinaclotide62$42,561
Mesalamine27$14,147
Mesalamine ErMesalamine13$11,354
Lubiprostone35$7,963
Ursodiol13$2,426
Omeprazole129$2,286
CholestyramineCholestyramine (With Sugar)13$2,276
Pantoprazole Sodium88$1,432
Esomeprazole Magnesium23$1,069
Lactulose15$837
Dicyclomine Hcl41$739
LoperamideLoperamide Hcl28$710
Lansoprazole12$533
Famotidine33$366

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$227$101,59379 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Holland

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →